The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1291
Duloxetine (Cymbalta) for Fibromyalgia
The full article is available to subscribers Subscriber Login   

Duloxetine (Cymbalta– Lilly) is the second drug to be approved by the FDA for treatment of fibromyalgia. Pregabalin (Lyrica), which is also approved for treatment of neuropathic pain and epilepsy, was the first.1 Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is already marketed for treatment of depression and diabetic neuropathy.2,3

FIBROMYALGIA — A chronic disorder mainly affecting women, fibromyalgia is characterized by diffuse musculoskeletal pain and is often associated with fatigue, irritable bowel symptoms and sleep problems. It has been treated with many different drugs, including analgesics, muscle relaxants, anticonvulsants, and antidepressants, particularly the tricyclic antidepressant amitriptyline (Elavil, and others). Non-drug treatments such as exercise and cognitive behavioral therapy have also ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Duloxetine (Cymbalta) for Fibromyalgia
Article code: 1291a
 Electronic, downloadable article - $25